PEA (100 caps)

Capsules of naturally occurring fatty acid amide which affects endocannabinoid signalling.

PEA may help relieve pain, itch and inflammation. 

PEA is a naturally occurring fatty acid amide which affects endocannabinoid signalling. PEA achieves its analgesic effects via indirect activation of the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors; as well as indirect activation of PPAR-alpha, and several other receptors.

PEA has been explored since 1957 and has a clear analgesic and anti-inflammatory efficacy, and virtually no side effects. Meanwhile within the context of clinical trials 5000 patients have been using PEA, and its efficacy and safety has been documented in more than 500 scientific papers.

PEA is referred to as a natural painkiller and anti-inflammatory compound. PEA is produced in our cells and found in some foods.

It is proven to be effective and safe in many human clinical trials in more than 5000 patients and can be combined with any other compound, allowing it to be used as part of a multi-faceted treatment plan for pain management and skin support for your pets.

Ingredients

Ultra-micronised Palmitoylethanolamide (P.E.A) in a cellulose capsule.

Directions & Dosage

Give according to your pet’s weight twice daily morning & night as close to 12 hours apart as possible, or as recommended by your animal healthcare professional. Can be given with or without food. 

Dosage is on bottle.

Which mg to order?

1-20kg 300mg

20-30kg 600mg

30-65kg 1000mg

For canine use only. Keep out of reach of children.

Storage

Store below 25 degrees Celsius. Keep in a cool dry place out of direct sunlight. Keep container tightly closed.

The Science

Abramo, F., Campora, L., Albanese, F., della Valle, M. F., Cristino, L., Petrosino, S., ... & Miragliotta, V. (2014). Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Veterinary Research, 10, 1-10.

Cerrato, S., Brazis, P., Della Valle, M. F., Miolo, A., Petrosino, S., Di Marzo, V., & Puigdemont, A. (2012). Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. The Veterinary Journal, 191(3), 377-382.

della Rocca, G.; Re, G. Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art. Biomolecules 2022, 12, 1186. https://doi.org/10.3390/biom12091186

della Rocca G, Gamba D. Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide? Animals. 2021; 11(4):952. https://doi.org/10.3390/ani11040952

Gugliandolo E, Peritore AF, Piras C, Cuzzocrea S, Crupi R. Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing. Veterinary Sciences. 2020; 7(2):78. https://doi.org/10.3390/vetsci7020078

Noli, C., Della Valle, M. F., Miolo, A., Medori, C., Schievano, C., & Skinalia Clinical Research Group. (2015). Efficacy of ultra‐micronized palmitoylethanolamide in canine atopic dermatitis: an open‐label multi‐centre study. Veterinary dermatology, 26(6), 432-e101.

Petrosino, S., Schiano Moriello, A., Cerrato, S., Fusco, M., Puigdemont, A., De Petrocellis, L., & Di Marzo, V. (2016). The anti‐inflammatory mediator palmitoylethanolamide enhances the levels of 2‐arachidonoyl‐glycerol and potentiates its actions at TRPV1 cation channels. British Journal of Pharmacology, 173(7), 1154-1162.

Re, G., Barbero, R., Miolo, A., & Di Marzo, V. (2007). Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. The Veterinary Journal, 173(1), 21-30.

Scuderi C, Golini L. Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention. Animals. 2021; 11(9):2584. https://doi.org/10.3390/ani11092584